Medicare AdvantageCoverageMedium impact
MA08.188a, Linvoseltamab-gcpt (Lynozyfic)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.188a for Linvoseltamab-gcpt (Lynozyfic) has been updated, effective January 1, 2026. This appears to be a new or revised coverage policy for this specialized medication, likely affecting prior authorization, coverage criteria, or billing requirements for this drug.
Action Required
Before January 1, 2026: Review the complete policy MA08.188a for Linvoseltamab-gcpt (Lynozyfic) at the provided URL to understand specific coverage criteria, prior authorization requirements, and billing procedures. Update billing workflows and staff training as needed based on the detailed policy requirements.